SCHEMBL483896

SCHEMBL483896

COC(=O)CNc1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.55
ALOX15 P16050 4/20 0.55
MAPK1 P28482 2/20 0.55
HTT P42858 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
NPC1 O15118 4/20 0.53
RAB9A P51151 3/20 0.53
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 4/20 0.52
HSD17B10 Q99714 2/20 0.52
LDHA P00338 1/20 0.52
LDHB P07195 1/20 0.52
MAPT P10636 2/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 2/20 0.50
MTOR P42345 1/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
KDM4E B2RXH2 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8425436 0.86 NPC1 (0.58) GAAALOX15MAPK1HTTL3MBTL1
SCHEMBL5216754 0.81 HTT (0.63) GAAALOX15MAPK1HTTL3MBTL1
SCHEMBL12126882 0.81 HPGD (0.61) GAAALOX15MAPK1HTTL3MBTL1
SCHEMBL484019 0.79 GAA (0.48) GAAALOX15MAPK1HTTL3MBTL1
SCHEMBL20922083 0.78 HTT (0.66) HTTL3MBTL1NPC1RAB9AKMT2A
SCHEMBL27627548 0.78 HTT (0.52) GAAALOX15MAPK1HTTL3MBTL1
SCHEMBL2406029 0.77 HTT (0.58) MAPK1HTTL3MBTL1NPC1RAB9A
SCHEMBL16393619 0.77 HTT (0.50) GAAALOX15MAPK1HTTL3MBTL1
SCHEMBL6988691 0.77 HTT (0.67) ALOX15MAPK1HTTL3MBTL1NPC1
SCHEMBL15546417 0.77 NPC1 (0.69) HTTL3MBTL1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US claimed
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP disclosed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP disclosed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives OXA1L, AAAS, MLYCD GAA 2145/4885ALOX15 2423/4885MAPK1 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.